These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29079660)

  • 1. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR
    Hsu PY; Wu VS; Kanaya N; Petrossian K; Hsu HK; Nguyen D; Schmolze D; Kai M; Liu CY; Lu H; Chu P; Vito CA; Kruper L; Mortimer J; Chen S
    Clin Cancer Res; 2018 Jan; 24(2):395-406. PubMed ID: 29079660
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Zhao M; Scott S; Evans KW; Yuca E; Saridogan T; Zheng X; Wang H; Korkut A; Cruz Pico CX; Demirhan M; Kirby B; Kopetz S; Diala I; Lalani AS; Piha-Paul S; Meric-Bernstam F
    Clin Cancer Res; 2021 Mar; 27(6):1681-1694. PubMed ID: 33414137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Petrossian K; Nguyen D; Lo C; Kanaya N; Somlo G; Cui YX; Huang CS; Chen S
    Breast Cancer Res Treat; 2018 Aug; 170(3):499-506. PubMed ID: 29623577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
    Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
    Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
    Casadevall D; Hernández-Prat A; García-Alonso S; Arpí-Llucià O; Menéndez S; Qin M; Guardia C; Morancho B; Sánchez-Martín FJ; Zazo S; Gavilán E; Sabbaghi MA; Eroles P; Cejalvo JM; Lluch A; Rojo F; Pandiella A; Rovira A; Albanell J
    Mol Cancer Res; 2022 Jul; 20(7):1108-1121. PubMed ID: 35348729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
    Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
    Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
    PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
    Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
    Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER
    Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F; Cutler RE; Lalani AS; Bryce R; Auerbach A; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(2):771-783. PubMed ID: 30274983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
    Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
    BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.